Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

by McCormack, Mary M , Dutta, Lea , Shapira-Frommer, Ronnie , Colombo, Nicoletta , Sakata, Jun , Makker, Vicky , Sanli, Ulus A , Santin, Alessandro D , Colomba, Emeline , Guerra, Eva M , Miller, David S , Fujiwara, Keiichi , Bird, Steven , Ray-Coquard, Isabelle , Kim, Yong Man , Ushijima, Kimio , Smith, Alan D , Pignata, Sandro , Baron-Hay, Sally , Yonemori, Kan , Keefe, Stephen , Orlowski, Robert J , Casado Herráez, Antonio , Lorusso, Domenica

in Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Cancer / Cancer therapies / Chemotherapy / Confidence intervals / Doxorubicin / Endometrial cancer / Endometrial Neoplasms / Endometrial Neoplasms - drug therapy / Endometrial Neoplasms - mortality / Endometrium / Female / Gynecologic Oncology / Gynecology / Hematology / Humans / Immunotherapy / Life Sciences / Middle Aged / Mismatch repair / Monoclonal antibodies / Obstetrics / Oncology / Oral administration / Paclitaxel / Patients / Pembrolizumab / Phenylurea Compounds / Phenylurea Compounds - administration & dosage / Phenylurea Compounds - adverse effects / Platinum / Population / Quinolines / Quinolines - administration & dosage / Quinolines - adverse effects / Santé publique et épidémiologie / Solid tumors / Survival / Survival Analysis / Targeted cancer therapy / Treatments in Oncology / Vascular endothelial growth factor

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

2022

Confirm

Do you wish to request the book?

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

McCormack, Mary M,

Dutta, Lea,

Shapira-Frommer, Ronnie,

Colombo, Nicoletta,

Sakata, Jun,

Makker, Vicky,

Sanli, Ulus A,

Santin, Alessandro D,

Colomba, Emeline,

Guerra, Eva M,

Miller, David S,

Fujiwara, Keiichi,

Bird, Steven,

Ray-Coquard, Isabelle,

Kim, Yong Man,

Ushijima, Kimio,

Smith, Alan D,

Pignata, Sandro,

Baron-Hay, Sally,

Yonemori, Kan,

Keefe, Stephen,

Orlowski, Robert J,

Casado Herráez, Antonio,

Lorusso, Domenica

2022

Overview

Women with advanced endometrial cancer that progressed during platinum-containing therapy were randomly assigned to lenvatinib plus pembrolizumab or physician’s choice of chemotherapy (doxorubicin or paclitaxel). The median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months and 11.4 months, respectively.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal, Humanized

/ Antibodies, Monoclonal, Humanized - administration & dosage

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols